GPC3 and hepatocellular carcinoma: Here we tested whether CYT-303, a bispecific multifunctional antibody that utilizes NKp46 to engage NK cells and GPC3 to target HCC, can induce NK cell cytotoxicity, cytokine production, ADCP, and CDC to kill HCC tumors and have the potential to be developed as a clinically relevant therapeutic against HCC.